In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Shifts Upstream

Executive Summary

Shire's latest acquisition, of Canada's BioChem Pharma, is its sixth in as many years, and the clearest sign yet of the shift which the UK-based specialty pharmaceutical company has to make towards earlier-stage research in order to keep up its impressive growth. Behind this growth is its low-risk Search & Development strategy: it seeks out promising, undervalued specialist-market drugs which it develops for new indications, or else finds new formulations for, after which it hands them on to its highly focused marketing and sales teams. A series of acquisitions-bolting on products, development programs and skills-has allowed Shire to quickly expand globally and broaden its portfolio. But as drugs get harder to find and more expensive, the company has had to throw its S&D net wider.
Advertisement

Related Content

Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Shire: Remodeling Specialty Pharma
Shire: Remodeling Specialty Pharma
Cephalon: Can Spec Pharma do R&D?
Cephalon: Can Spec Pharma do R&D?
Shire/TKT: The Price of Diversification
Shire: Proving the Specialty Model
Mid-Sized Pharma in Mega-Sized Markets

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel